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A B S T R A C T
Upon various stimulations, mast cells (MCs) release a wide variety of chemical mediators stored in their
cytoplasmic granules, which then initiates subsequent allergic reactions. Lysophosphatidylserine (LysoPS), a
kind of lysophospholipid, potentiates the histamine release from MCs triggered by antigen stimulation. We
previously showed through structure-activity studies of LysoPS analogs that LysoPS with a methyl group at the
carbon of the serine residue, i.e., lysophosphatidylthreonine (LysoPT), is extremely potent in stimulating the
MC degranulation. In this study, as our continuing study to identify more potent LysoPS analogs, we developed
LysoPS analogs with fatty acid surrogates. We found that the substitution of oleic acid to an aromatic fatty acid
surrogate (C3-pH-p-O-C11) in 2-deoxy-1-LysoPS resulted in signiﬁcant increase in the ability to induce MCs
degranulation compared with 2-deoxy-1-LysoPS with oleic acid. Conversion of the serine residue into the
threonine residue further increased the activity of MC degranulation both in vitro and in vivo. The resulting
super agonist, 2-deoxy-LysoPT with C3-pH-p-O-C11, will be a useful tool to elucidate the mechanisms of
stimulatory eﬀect of LysoPS on MC degranulation.
1. Introduction
Mast cells (MCs) play a critical role in immediate-type allergic
reactions triggered by antigen binding–induced cross-linking of IgE-
bound FcεRI (a high-aﬃnity receptor for IgE) and the resulting release
of chemical mediators such as histamine and serotonin from their
secretary granules, a process known as MC degranulation [1,2]. The
released histamine from MCs can cause allergic diseases such as
pollinosis, urticaria, atopic dermatitis, and asthma. Identiﬁcation of
factors that modulate MC degranulation would be helpful in providing
tools to investigate the molecular mechanisms of allergic reactions as
well as to develop anti-allergic drugs.
Lysophosphatidylserine (LysoPS; 1-acyl-2-lyso-PS or 1-lyso-2-acyl-
PS) has several biological activities, including a promotion of neurite
outgrowth, a suppression of T lymphocyte proliferation and an
enhancement of MC degranulation [3]. Among them, the most
characterized biological action of LysoPS is its action to MCs.
Exogenous phosphatidylserine (PS) or LysoPS strongly enhances the
degranulation of rat peritoneal MCs (RPMCs) initiated by FcεRI cross-
linking [4,5]. Because LysoPS is ∼1000 times more active than PS and
LysoPS is readily produced from PS, LysoPS is considered as the true
eﬀector for MCs [5]. The action of LysoPS is highly speciﬁc; all other
lysophospholipids (including lysophosphatidyl-D-serine, an optical
isomer of lysophosphatidyl-L-serine) are reported to be ineﬀective
[6]. Thus, a speciﬁc receptor for LysoPS should exist on the plasma
membrane of RPMCs.
Four G protein-coupled receptors (GPCRs) (LPS1/GPR34, LPS2/
P2Y10, LPS2L/A630033H20Rik and LPS3/GPR174) that were speciﬁ-
cally activated by LysoPS have been proposed as candidate MC LysoPS
receptors [8,9]. However, they do not appear to be MC LysoPS
receptors because none of them reacted with the super agonist,
lysophosphatidylthreonine (LysoPT; see below) [10]. In addition,
MCs isolated from LPS1/GPR34-deﬁcient mice were still activated by
LysoPS [11]. Thus, the LysoPS receptor on MC has not been identiﬁed
yet.
For molecular identiﬁcation of unknown receptor, speciﬁc agonists
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with potent activity are deﬁnitely useful. We previously synthesized a
series of chemically modiﬁed LysoPS (so-called LysoPS analogs) and
tested their ability to promote antigen-induced RPMC degranulation
and to activate cloned LysoPS receptors (i.e., LPS1/GPR34, LPS2/
P2Y10 and LPS3/GPR174) [10,12,13]. In these studies, LysoPS was
regarded as a modular assembly of serine, phosphate, glycerol and fatty
acid and modiﬁed each module. Indeed, we developed several LysoPS
analogs containing simple modiﬁcations in individual modules that
were found to be potent inducers of MC degranulation, but were
incapable of activating the cloned LysoPS receptors. In the ﬁrst round
of our study, modiﬁcation was focused on the serine and glycerol
modules. As a result, a LysoPS analog with an addition of a methyl
group at the carbon of the serine residue, i.e., LysoPT, was identiﬁed as
a potent LysoPS analog in promoting antigen-elicited MC degranula-
tion [10]. In the second round, the modiﬁcation was focused on the
fatty acid module and a number of LysoPS analogs with fatty acid
module and aromatic fatty acid modiﬁcations were generated [12,13].
Here, a number of these analogs were evaluated for their ability to
promote antigen-induced MC degranulation. We identiﬁed an aromatic
fatty acid surrogate that greatly enhanced the degranulation-promoting
activity of LysoPS. By introducing this surrogate into the structure of 2-
deoxy-1-LysoPT, we created a super agonist with ~100-fold higher
activity than LysoPS.
2. Methods
2.1. Materials
Oleoyl (18:1)-LysoPS was purchased from Avanti Polar Lipids.
LysoPS analogs except 2-deoxy-1-C3-pH-p-O-C11-LysoPT were
synthesized as described previously [10,13], and the chemical structure
was conﬁrmed by nuclear magnetic resonance (NMR) and element
analysis. We conﬁrmed that the purity of LysoPS analogs was always
more than 95%. All rats and mice were purchased from Japan SLC.
2.2. Mast cell degranulation assay in vitro
MCs from the peritoneal cavity of rats and mice were prepared
essentially as previously described [10]. The MCs were puriﬁed by
Percoll (GE Healthcare) in HEPES-buﬀered Tyrode (HBT) solution (pH
7.4) and suspended at a cell density of 5×104/mL (in 0.2 mL) in HBT
solution containing 0.01% BSA and stimulated with the indicated dose
of each LysoPS analog (nM–µM) in the presence of concanavalin A
(Sigma Aldrich) (100 µg/mL for RPMC and 10 µg/mL for mouse
peritoneal MCs), which is known to cross-link the FcεRI receptor, at
37 °C. After 15 min, cells were added with cold 0.01% BSA/ HBT
solution to stop the degranulation reaction. Then, cell suspensions
were centrifuged for 5 min at ×860g. The histamine content in the
supernatant was determined by the o-phthalaldehyde (OPA) ﬂuoro-
metric assay as shown below [10,14]. HCl (1 M) was added to the
supernatant for measuring the total histamine. Next NaOH (1 M) was
added, followed by OPA reagent. After 4 min, HCl (3 M) was added to
stop the OPA reaction. The solution was then transferred to black 96-
well ﬂat bottom plate (Greiner) and the ﬂuorescence at 450 nm
resulting from excitation at 360 nm was measured using a microplate
reader (FlexStation3, Molecular Devices). Histamine release was
calculated as a percentage of the total histamine recovered from non-
stimulated cells (treated with 0.01% BSA/HBT solution). Values that
are subtracted by that of negative control group are shown in Figure.
Values for histamine release are presented as the means ± SE for
several replicate experiments on diﬀerent samples of pooled cells, each
in triplicate. All animal procedures were done according to the guide-
lines for care and use of laboratory animals approved by Tohoku
University.
2.3. Evaluation of hypothermic eﬀect of LysoPS analogs
LysoPS and LysoPS analogs were dissolved in PBS containing 0.1%
bovine serum albumin and were injected intravenously into mice.
Rectal temperatures were measured with an electronic thermometer
(Physitemp Instruments) every 5 or 10 min for 70 min
2.4. TGFα shedding assay
Transforming growth factor α (TGFα) shedding assay was per-
formed as previously described [9]. Brieﬂy, HEK293A (for LPS1 and
LPS2) or HEK293FT (for LPS3) cells were transfected with two kinds of
plasmids vectors encoding LysoPS receptors and alkaline phosphatase-
tagged TGFα. For LPS1, a plasmid vector encoding Gαq/i1 was co-
transfected [12,15]. After 24 h, cells were harvested and mixed with a
test compound for 1 h. Compound-induced AP-TGFα release from cells
was evaluated by determining the AP activity in the conditioned media.
Values for AP-TGFα release were presented as the means ± SD for three
independent experiments, each in triplicate.
2.5. Synthesis of 2-deoxy-1-C3-pH-p-O-C11-LysoPT
2-deoxy-1-C3-pH-p-O-C11-LysoPT was synthesized from L-threo-
nine, mono-protected propane-1, 3-diol and fatty acid surrogate (C3-
pH-p-O-C11) in a similar manner as in [13]: mono-protected propane-
1,3-diol, i.e., 3-((tert-butyldimethylsilyl)oxy)propan-1-ol, synthesized
from propane-1,3-diol, was connected with O-phosphanyl N- and C-
terminal-diprototected L-threonine, tert-butyl O-(tert-butoxy(diisopro-
pylamino)phosphanyl)-N-(tert-butoxycarbonyl)-L-threoninate by
using phosphoramidite method. After removing the protective group
(a tert-butyldimethylsilyl group) from the alcohol moiety, the free
hydroxyl group was esteriﬁed with the fatty acid surrogate (C3-pH-p-
O-C11), to yield protected. Global deprotection with TFA (triﬂuoroa-
cetic acid) and puriﬁcation by silica gel column chromatography
furnished the 2-deoxy-1-LysoPT analog. 2-deoxy-1-C3-pH-p-O-C11-
LysoPT as TFA salt (0.67 TFA) satisﬁed elemental analysis (Purity: >
99.7%). HPLC purity (area normalization method): 95%.
3. Results and discussion
3.1. LysoPS analogs with an aromatic fatty acid surrogate, C3-pH-p-
O-C11, is a potent mast cell degranulation inducer
The structure of LysoPS analogs used in this study is shown in
(Fig. 1). Because of the ease of chemical synthesis and the fact that they
don’t require a sn-2 hydroxy group of LysoPS for MC degranulation-
inducing activity, most of the LysoPS analogs tested in this study did
not have the sn-2 hydroxy group (deoxy-LysoPS analogs). We replaced
the fatty acid of LysoPS with various aromatic fatty acid surrogates
(Fig. 1). The LysoPS analogs tested were 2-deoxy-1-C3-pH-o-O-C7-
lysophosphatidylserine (LysoPS), 2-deoxy-1-C3-pH-o-O-C9-LysoPS, 2-
deoxy-1-C3-pH-o-O-C11-LysoPS, 2-deoxy-1-C3-pH-m-O-C11-LysoPS
and 2-deoxy-1-C3-pH-p-O-C11-LysoPS. Each LysoPS analog (+ a
previously characterized deoxy-1-LysoPS (18:1) and LysoPS (18:1))
was tested for their ability to stimulate concanavalin A-induced MC
degranulation from RPMC. The reactivity of each LysoPS analog in
stimulating MC degranulation, as judged by histamine release from
RPMCs, is shown in Fig. 2. and the results are summarized in Table 1.
Modiﬁcation of the fatty acid module signiﬁcantly aﬀected the degra-
nulation-stimulating activity of LysoPS. Among the 2-deoxy-1-LysoPS
analogs with fatty acid surrogates, 2-deoxy-1-C3-pH-p-O-C11-LysoPS
showed the highest activity with an EC50 value about 40 nM (Fig. 2 and
Table 1).
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3.2. 2-deoxy-1-C3-pH-p-O-C11-LysoPT is the most potent mast cell
degranulation inducer
Because conversion of serine polar head to threonine dramatically
enhanced the activity to stimulate degranulation reaction of LysoPS
[10], we thus synthesized 2-deoxy-1-C3-pH-p-O-C11-LysoPT (Fig. 1)
and tested its ability to stimulate degranulation reaction (Fig. 3A and
Table 2). The resulting LysoPT analog, 2-deoxy-1-C3-pH-p-O-C11-
LysoPT, was extremely potent in stimulating degranulation from
RPMCs, with EC50 value about 3 nM. We also conﬁrmed that 2-
deoxy-1-C3-pH-p-O-C11-LysoPT was the most potent for inducing
degranulation of mouse peritoneal MCs with EC50 value about 3 nM
(Fig. 3B and Table 2).
Fig. 1. Chemical structures of LysoPS analogs used in this study.
Fig. 2. Identiﬁcation of C3-pH-p-O-C11 as the module that confer the greatest MC degranulation activity LysoPS (18:1) and 2-deoxy-LysoPS analogs with diﬀerent fatty acid surrogates
(Fig. 1) were tested for their ability to induce histamine release from concanavalin A-treated RPMCs. Released histamine, expressed as a percent of the total cell histamine, was
determined by ﬂuorometric assay. Values are the means ± SE of four independent experiments, each performed in duplicate.
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3.3. In vivo hypothermic eﬀect
Intravenous injection of 100 µg of LysoPS in mice induced transient
hypothermia due to systemic MC degranulation [10]. We focused four
LysoPS analogs and LysoPS (18:1) and tested their hypothermic
eﬀects. Mice were injected i.v. with the potent LysoPS analogs, and
decrease in the rectal temperature was measured. Unlike LysoPS, only
5 or 10 µg i.v. injection of 2-deoxy-1-C3-pH-p-O-C11-LysoPT induced
dramatic hypothermia. The rank order matched to that observed for in
vitro degranulation-stimulating activity (Fig. 4). Again, 2-deoxy-1-C3-
pH-p-O-C11-LysoPT was induced the greatest hypothermic action.
3.4. 2-deoxy-1-C3-pH-p-O-C11-LysoPT did not activate LPS1-3
To examine if 2-deoxy-1-C3-pH-p-O-C11-LysoPT activates LPS1–3,
we used TGFα shedding assay. While LysoPS activated all the three
LysoPS receptors in TGFα shedding assay, 2-deoxy-1-C3-pH-p-O-C11-
LysoPT didn’t (Fig. 5). These results suggest that the putative LysoPS
receptor on MCs is diﬀerent from the cloned GPCR-type LysoPS
receptors.
Lysophosphatidylserine (LysoPS) is composed of four modules, i.e.,
a serine, a phosphate, a glycerol and a fatty acid, which are chemically
linked by phosphodiester or ester bonds. We previously examined
structure-activity relationship (SAR) of LysoPS by synthesizing a
number of LysoPS analogs with modiﬁcations of the four modules,
and by evaluating them for both MC degranulation and activation of
the cloned GPCR-type LysoPS receptors (LPS1, LPS2 and LPS3)
[10,12,13]. Initially our modiﬁcation was focused exclusively on serine
and glycerol modules [10]. As a result, threonine was found to be
superior to serine for MC degranulation. In this study, to identify a
preferable fatty acid module, we used a new set of LysoPS analogs with
modiﬁcation in the fatty acid module [13]. We ﬁrst identiﬁed C3-pH-p-
O-C11 as the fatty acid module that conferred the greatest MC
degranulation activity (Fig. 2 and Table 1). Introducing the fatty acid
surrogate into the structure of a potent ligand, 2-deoxy-1-LysoPT,
made it possible to identify a super agonist, i.e., 2-deoxy-1-C3-pH-p-O-
C11-LysoPT. Indeed, the activities of the resulting LysoPS analogs
showed 100 times higher than LysoPS (18:1) both in vitro (Fig. 3 and
Table 2) and in vivo (Fig. 4). The SAR for MC degranulation obtained in
this study was diﬀerent from the SAR for the LysoPS receptors (LPS1,
LPS2 and LPS3) [13]. It should be noted that 2-deoxy-1-C3-pH-o-O-
C11-LysoPS, a poor inducer of MC degranulation (Fig. 2 and Table 1),
was actually a potent agonist for cloned GPCR-type LysoPS receptors
[13]. We previously showed that 1-stearoyl (18:0)-LysoPS is a potent
agonist for MC degranulation [10], while it was poor agonist for all the
cloned GPCR-type LysoPS receptors. By contrast, LysoPS with un-
saturated fatty acid such as oleic acid (18:1) and arachidonic acid
(20:4) was preferable ligand for cloned GPCR-type LysoPS receptors.
Thus, it is reasonable to assume that the ligand recognizing pocket of
putative MC LysoPS receptor is quite diﬀerent from those of cloned
GPCR-type LysoPS receptors. Taking account of the fact that the
structure of C3-pH-p-O-C11 is more linear than C3-pH-o-O-C11
(Fig. 1), it can be speculated the pocket of the putative MC LysoPS
receptor accommodates to linear fatty acids, while those of the cloned
GPCR-type LysoPS receptors accommodate to bended or curved fatty
acids. We also conﬁrmed that 2-deoxy-1-C3-pH-p-O-C11-LysoPT
activated none of the cloned GPCR-type LysoPS receptors in TGFα
shedding assay (Fig. 5), suggesting again that the ligand binding
manner of MC LysoPS receptor is diﬀerent from those of the cloned
GPCR-type LysoPS receptors.
Table 1
EC50 values of LysoPS analogs for rat peritoneal mast cell degranulation.
LysoPS or LysoPS analogs EC50
LysoPS (18:1) ~150 nM
2-deoxy-1-LysoPS (18:1) ~200 nM
2-deoxy-1-C3-pH-o-O-C7-LysoPS > 500 nM
2-deoxy-1-C3-pH-o-O-C9-LysoPS ~300 nM
2-deoxy-1-C3-pH-o-O-C11-LysoPS ~300 nM
2-deoxy-1-C3-pH-m-O-C11-LysoPS ~100 nM
2-deoxy-1-C3-pH-p-O-C11-LysoPS ~40 nM
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Fig. 3. 2-deoxy-1-C3-pH-p-O-C11-LysoPT is a super agonist for MC degranulation 2-deoxy-1-C3-pH-p-O-C11-LysoPT and related compounds (LysoPS (18:1), LysoPT (18:1) and 2-
deoxy-1-C3-pH-p-O-C11-LysoPS for comparison) were tested for their ability to induce histamine release from concanavalin A-treated rat (A) and mouse (B) peritoneal MCs. Released
histamine was determined by ﬂuorometric assay and the histamine release is expressed as a percent of the total cell histamine. Values are the means ± SE of three independent
experiments, each in duplicate. Each symbol represents; closed circle (•) 2-deoxy-1-C3-pH-p-O-C11-LysoPT, open circle (○) LysoPT (18:1), closed triangle (▲) 2-deoxy-1-C3-pH-p-O-
C11-LysoPS and open triangle (△) LysoPS (18:1).
Table 2
EC50 values of LysoPS analogs for rat (RMPC) and mouse (MPMC) peritoneal mast cell
degranulation.
LysoPS or LysoPS analogs EC50 EC50
RPMC MPMC
LysoPS (18:1) ~150 nM ~80 nM
LysoPT (18:1) ~10 nM ~7 nM
2-deoxy-1-C3-pH-p-O-C11-LysoPS ~40 nM ~30 nM
2-deoxy-1-C3-pH-p-O-C11-LysoPT ~3 nM ~3 nM
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In summary, we have identiﬁed a potent LysoPS analog, 2-deoxy-1-
C3-pH-p-O-C11-LysoPT, which induced MC degranulation at nM
concentration. The super agonist should be useful not only for
pharmacological characterization of the MC LysoPS receptor but also
for biochemical identiﬁcation of the receptor.
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